Stifel raised the firm’s price target on Compass Pathways (CMPS) to $14 from $11 and keeps a Buy rating on the shares. The firm reiterated its Buy view following Q4 earnings, where completion of the rolling NDA is on track for 4Q26. With recent positive topline from Part-A of the ‘006 Phase 3 study, plus encouraging 26-week durability from Part B of the ‘005 study, Compass plans to meet with the FDA to confirm alignment on the rolling submission and the path to approval, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways price target lowered to $16 from $18 at Morgan Stanley
- Compass Pathways reports Q4 EPS ($1.00) vs. (63c) last year
- Compass Pathways sees cash runway into 2028
- Neuronetics price target lowered to $3 from $7 at Canaccord
- COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating